Literature DB >> 24970695

Angiographic evaluation of hepatic arterial injury after cisplatin and Gelfoam-based transcatheter arterial chemoembolization for hepatocellular carcinoma in a 205 patient cohort during a 6-year follow-up.

C H Suh1, J H Shin, H M Yoon, H-K Yoon, G-Y Ko, D-I Gwon, J-H Kim, K-B Sung.   

Abstract

OBJECTIVE: To evaluate the overall and cumulative incidence, degree, interval change and predictors of hepatic arterial injury (HAI) after cisplatin and Gelfoam® (Upjohn, Kalamazoo, MI)-based transcatheter arterial chemoembolization (TACE) for hepatocellular carcinoma (HCC).
METHODS: A total of 205 patients with HCC who underwent three or more sessions of TACE without additional surgical or local treatment were included. HAI was evaluated at each segment of the hepatic artery using a three-grade scale: 1 (slight wall irregularity), 2 (overt stenosis) and 3 (occlusion). HAI interval change was categorized into three groups: progression, stable state and improvement. Cumulative incidence of HAI was analysed using Kaplan- Meier method, and predictors of HAI (patient age, sex, portal vein thrombosis and Child-Pugh classification) were analysed by univariate logistic regression.
RESULTS: HAI occurred in 50 of the 205 study patients (24.4%). The cumulative incidence of HAI was 16.0% [95% confidence interval (CI), 10.21-21.77] during 5 sessions of TACE, 52.1% (95% CI, 37.83-66.29) during 10 sessions and 68.0% (95% CI, 67.62-88.46) during 15 sessions. Initial HAI was interpreted as grades 1, 2 and 3 in 11 (22.0%), 17 (34.0%) and 22 (44.0%) patients, respectively. When the interval change was assessed in 48 patients with available follow-up TACE, 40 (83.3%) were included in the progression, 2 (4.2%) in the stable state and 6 (12.5%) in the improvement groups. The univariate analysis used to determine the predictors of HAI revealed no significant predictors.
CONCLUSION: In three or more sessions of TACE, the incidence of HAI was 24%. Increasing TACE causes increased incidence of HAI. The initial presentation was most commonly grade 3, and 12.5% of the patients with HAI showed improvement of the HAI grade during follow-up TACE. ADVANCES IN KNOWLEDGE: In patients who underwent three or more sessions of cisplatin and Gelfoam-based TACE, the overall incidence of HAI was 24.4%, and increasing TACE causes increased incidence of HAI.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24970695      PMCID: PMC4453139          DOI: 10.1259/bjr.20140054

Source DB:  PubMed          Journal:  Br J Radiol        ISSN: 0007-1285            Impact factor:   3.039


  12 in total

1.  Transcatheter arterial chemoembolization of liver tumors: effects of embolization protocol on injectable volume of chemotherapy and subsequent arterial patency.

Authors:  Jean-Francois H Geschwind; Douglas E Ramsey; Berry Cleffken; B C H van der Wal; Hicham Kobeiter; Krishna Juluru; George G Hartnell; Michael A Choti
Journal:  Cardiovasc Intervent Radiol       Date:  2003-03-06       Impact factor: 2.740

2.  Study of severe and rare complications of transarterial chemoembolization (TACE) for liver cancer.

Authors:  Jinglin Xia; Zhenggang Ren; Shenglong Ye; Dilip Sharma; Zhiying Lin; Yuhong Gan; Yi Chen; Ninglin Ge; Zengchen Ma; Zhiquan Wu; Jia Fan; Lunxiu Qin; Xinda Zhou; Zhaoyou Tang; Binghui Yang
Journal:  Eur J Radiol       Date:  2006-04-18       Impact factor: 3.528

3.  Transcatheter oily chemoembolization of the inferior phrenic artery in hepatocellular carcinoma: the safety and potential therapeutic role.

Authors:  J W Chung; J H Park; J K Han; B I Choi; T K Kim; M C Han
Journal:  J Vasc Interv Radiol       Date:  1998 May-Jun       Impact factor: 3.464

4.  Complications associated with transcatheter arterial embolization for hepatic tumors.

Authors:  I Sakamoto; N Aso; K Nagaoki; Y Matsuoka; M Uetani; K Ashizawa; S Iwanaga; M Mori; M Morikawa; T Fukuda; K Hayashi; N Matsunaga
Journal:  Radiographics       Date:  1998 May-Jun       Impact factor: 5.333

5.  Influential factors and formation of extrahepatic collateral artery in unresectable hepatocellular carcinoma.

Authors:  Yong-Li Wang; Ming-Hua Li; Ying-Sheng Cheng; Hai-Bing Shi; Hai-Lun Fan
Journal:  World J Gastroenterol       Date:  2005-05-07       Impact factor: 5.742

6.  A randomized clinical trial comparing autologous blood clot and gelfoam in transarterial chemoembolization for inoperable hepatocellular carcinoma.

Authors:  P C Kwok; T W Lam; S C Chan; C P Chung; W K Wong; M K Chan; H Y Lo; W M Lam
Journal:  J Hepatol       Date:  2000-06       Impact factor: 25.083

7.  Transcatheter oily chemoembolization of hepatocellular carcinoma.

Authors:  H Nakamura; T Hashimoto; H Oi; S Sawada
Journal:  Radiology       Date:  1989-03       Impact factor: 11.105

8.  Arteritis following intra-arterial chemotherapy for liver tumors.

Authors:  L Belli; G Magistretti; G P Puricelli; G Damiani; E Colombo; G P Cornalba
Journal:  Eur Radiol       Date:  1997       Impact factor: 5.315

9.  Recognizing extrahepatic collateral vessels that supply hepatocellular carcinoma to avoid complications of transcatheter arterial chemoembolization.

Authors:  Hyo-Cheol Kim; Jin Wook Chung; Whal Lee; Hwan Jun Jae; Jae Hyung Park
Journal:  Radiographics       Date:  2005-10       Impact factor: 5.333

10.  Angiographic evaluation of hepatic arterial damage after transarterial chemoembolization for hepatocellular carcinoma.

Authors:  Noboru Maeda; Keigo Osuga; Koji Mikami; Hiroki Higashihara; Hiromitsu Onishi; Yasuhiro Nakaya; Mitsuaki Tatsumi; Masatoshi Hori; Tonsok Kim; Kaname Tomoda; Hironobu Nakamura
Journal:  Radiat Med       Date:  2008-05-29
View more
  4 in total

1.  Initial Transarterial Chemoembolization (TACE) Using HepaSpheres 20-40 µm and Subsequent Lipiodol TACE in Patients with Hepatocellular Carcinoma > 5 cm.

Authors:  Su Min Cho; Hee Ho Chu; Jong Woo Kim; Jin Hyung Kim; Dong Il Gwon
Journal:  Life (Basel)       Date:  2021-04-18

2.  Whole-liver transcatheter arterial chemoinfusion and bland embolization with fine-powder cisplatin and trisacryl gelatin microspheres for treating unresectable multiple hepatocellular carcinoma.

Authors:  Akihiro Imamura; Hidetoshi Taguchi; Hideyuki Takano; Hiroyuki Funatsu; Kazuyoshi Nakamura; Hidehito Arimitsu; Satoshi Chiba
Journal:  Jpn J Radiol       Date:  2021-01-02       Impact factor: 2.374

3.  Balloon occluded TACE (B-TACE) vs DEM-TACE for HCC: a single center retrospective case control study.

Authors:  Pierleone Lucatelli; Gianluca De Rubeis; Bianca Rocco; Fabrizio Basilico; Alessandro Cannavale; Aurelio Abbatecola; Pier Giorgio Nardis; Mario Corona; Stefania Brozetti; Carlo Catalano; Mario Bezzi
Journal:  BMC Gastroenterol       Date:  2021-02-03       Impact factor: 3.067

4.  Uni-, Bi- or Trifocal Hepatocellular Carcinoma in Western Patients: Recurrence and Survival after Percutaneous Thermal Ablation.

Authors:  Ancelin Preel; Margaux Hermida; Carole Allimant; Eric Assenat; Chloé Guillot; Cecilia Gozzo; Serge Aho-Glele; Georges-Philippe Pageaux; Christophe Cassinotto; Boris Guiu
Journal:  Cancers (Basel)       Date:  2021-05-30       Impact factor: 6.639

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.